American prescription drug costs and import debate

By the Editorial Team · Sunday, October 18, 2026

Many Americans, particularly seniors on Medicare, are seeking lower-cost prescription drugs from Canadian pharmacies despite federal restrictions on imports. Advocates argue that allowing regulated drug importation could alleviate high domestic prices and reduce financial burdens on both patients and Medicare, while opponents raise concerns about safety and regulatory challenges.

Americans continue to face significant disparities in prescription drug prices, prompting ongoing debate over the possibility of importing medications from abroad. While Canadian pharmacies offer certain drugs at substantially lower prices, current U.S. regulations restrict these imports, particularly for Medicare recipients, who are barred from receiving discounts or rebates through the program.

A case in point involves the medication Lumigan, an eye drop treatment. In Canada, monthly costs for Lumigan can be as low as $71, translating to about $852 annually. In contrast, the same drug in the United States can run approximately $265 per month, or $3,180 annually. Under Medicare, patients typically must cover the first $2,100 out-of-pocket before insurance assistance kicks in, which poses a significant financial barrier for many seniors.

Some Americans over age 65 have turned to purchasing medications directly from Canadian pharmacies without using Medicare coverage, effectively reducing their annual expenses by roughly $1,000 for drugs like Lumigan. Supporters of imports argue that this approach offers practical savings while also easing the financial burden on Medicare itself.

Opponents, including pharmaceutical industry lobbyists, warn that drug importation carries substantial risks, citing concerns about safety and potential contamination. The U.S. Food and Drug Administration recently recalled nearly 4 million bottles of potentially contaminated eye drops, though those products originated from U.S.-based facilities, not Canadian pharmacies. The Canadian International Pharmacy Association (CIPA), which has established standards for cross-border pharmacy exports since 2002, maintains that Canadian pharmacies meet high safety and quality standards.

Critics of import restrictions highlight the contrasting track records of pharmaceutical companies. While Canadian pharmacies involved in export follow strict regulatory oversight, some major U.S.-based pharmaceutical manufacturers have faced billions of dollars in penalties and settlements related to illegal practices over recent decades. Agencies such as the Drug Enforcement Administration have also acted against pharmacies and drug companies violating controlled substances laws, indicating oversight mechanisms exist within the domestic market.

The debate is compounded by patent protections. For example, the patent on Lumigan is set to expire next summer, which could lead to lower prices domestically. However, many other medications without imminent patent expirations leave millions of Americans vulnerable to high costs. Tim Smith, general manager of CIPA, notes that many patients seek Canadian pharmacies simply because they cannot afford necessary medications in the United States.

Proponents of drug importation call for regulatory changes that would allow individuals greater freedom to obtain prescribed medications internationally without federal prohibitions. They argue that if it is legal to purchase drugs from a domestic pharmacy in Vancouver, Washington, it should reasonably be allowed to acquire the same drugs from Vancouver, Canada. Without such changes, critics caution, many Americans will continue to face prohibitive drug prices, undermining access to critical treatments.

This article was reported by synthesizing coverage from multiple independent news outlets to present a balanced, unbiased account. Read about our editorial standards. Spotted an error? Let us know.